CHROMOLOGIC LLC — Department of Defense SBIR Phase II: DHA211-007
CHROMOLOGIC LLC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,099,885 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code DHA211-007 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $1,099,885
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase II
- Topic
- DHA211-007
- Solicitation
- 21.1
- NAICS
- —
- Place of performance
- CA
- Period
- 2022-08-22 → 2024-12-28
Description
In order to meet the DoD’s need for a prophylactic medical countermeasure to reduce the risk of acute radiation syndrome (ARS) when taken before exposure to ionizing radiation, ChromoLogic proposes to develop multilamellar vesicle-encapsulation JP4-039 (JP4-039-MLV) as a radioprotector of ionizing radiation (IR)-induced health risks. DoD personnel, such as members of the Joint Forces, would self-administer JP4-039-MLV prior to operating in a known, high risk IR environment. A single dose of JP4-039-MLV would provide protection from ARS for 72 h. In Phase II, ChromoLogic will build on the successful in vivo demonstration of efficacy in Phase I by (i) optimizing the production of JP4-039-MLV nanoparticles to transition to GMP manufacturing; (ii) characterizing the pharmacokinetics of JP4-039-MLV nanoparticles; and, (iii) demonstrating the efficacy of JP4-039-MLV radioprotection in a murine model exposed to an ARS-inducing dose (LD70/30) of whole-body irradiation. In addition, ChromoLogic will prepare and FDA regulatory plan.